The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Wet Macular Degeneration Market Research Report 2025
Synopsis
Wet macular degeneration is a chronic eye disorder that induces vague vision or a blind spot in the patient's visual field.
The global Wet Macular Degeneration market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Wet Macular Degeneration, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Wet Macular Degeneration.
Report Scope
The Wet Macular Degeneration market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Wet Macular Degeneration market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Wet Macular Degeneration companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer Inc.
F. Hoffmann-La Roche AG
Regeneron Pharmaceuticals, Inc.
Novartis AG
Bausch Health Companies Inc.
Apellis Pharmaceuticals Inc.
GlaxoSmithKline plc
Ophthotech Corporation
Gilead Sciences, Inc.
Alcon
Genzyme Corporation
Boehringer Ingelheim GmbH
EyeGate Pharmaceuticals, Inc.
EyeCyte, Inc.
PanOptica Inc
Segment by Type
by Drug
Lucentis
Eylea
Avastin
Others
by Route of Administration
Intravitreal
Intravenous
Segment by Application
Hospitals
Clinics
Research Institutes
Academic Institutes
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Wet Macular Degeneration companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Wet macular degeneration is a chronic eye disorder that induces vague vision or a blind spot in the patient's visual field.
The global Wet Macular Degeneration market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Wet Macular Degeneration, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Wet Macular Degeneration.
Report Scope
The Wet Macular Degeneration market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Wet Macular Degeneration market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Wet Macular Degeneration companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer Inc.
F. Hoffmann-La Roche AG
Regeneron Pharmaceuticals, Inc.
Novartis AG
Bausch Health Companies Inc.
Apellis Pharmaceuticals Inc.
GlaxoSmithKline plc
Ophthotech Corporation
Gilead Sciences, Inc.
Alcon
Genzyme Corporation
Boehringer Ingelheim GmbH
EyeGate Pharmaceuticals, Inc.
EyeCyte, Inc.
PanOptica Inc
Segment by Type
by Drug
Lucentis
Eylea
Avastin
Others
by Route of Administration
Intravitreal
Intravenous
Segment by Application
Hospitals
Clinics
Research Institutes
Academic Institutes
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Wet Macular Degeneration companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Drug
1.2.1 Global Wet Macular Degeneration Market Size Growth Rate by Drug: 2019 VS 2023 VS 2030
1.2.2 Lucentis
1.2.3 Eylea
1.2.4 Avastin
1.2.5 Others
1.3 Market by Application
1.3.1 Global Wet Macular Degeneration Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Research Institutes
1.3.5 Academic Institutes
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Wet Macular Degeneration Market Perspective (2019-2030)
2.2 Wet Macular Degeneration Growth Trends by Region
2.2.1 Global Wet Macular Degeneration Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Wet Macular Degeneration Historic Market Size by Region (2019-2024)
2.2.3 Wet Macular Degeneration Forecasted Market Size by Region (2025-2030)
2.3 Wet Macular Degeneration Market Dynamics
2.3.1 Wet Macular Degeneration Industry Trends
2.3.2 Wet Macular Degeneration Market Drivers
2.3.3 Wet Macular Degeneration Market Challenges
2.3.4 Wet Macular Degeneration Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Wet Macular Degeneration Players by Revenue
3.1.1 Global Top Wet Macular Degeneration Players by Revenue (2019-2024)
3.1.2 Global Wet Macular Degeneration Revenue Market Share by Players (2019-2024)
3.2 Global Wet Macular Degeneration Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Wet Macular Degeneration Revenue
3.4 Global Wet Macular Degeneration Market Concentration Ratio
3.4.1 Global Wet Macular Degeneration Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Wet Macular Degeneration Revenue in 2023
3.5 Wet Macular Degeneration Key Players Head office and Area Served
3.6 Key Players Wet Macular Degeneration Product Solution and Service
3.7 Date of Enter into Wet Macular Degeneration Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Wet Macular Degeneration Breakdown Data by Type
4.1 Global Wet Macular Degeneration Historic Market Size by Type (2019-2024)
4.2 Global Wet Macular Degeneration Forecasted Market Size by Type (2025-2030)
5 Wet Macular Degeneration Breakdown Data by Application
5.1 Global Wet Macular Degeneration Historic Market Size by Application (2019-2024)
5.2 Global Wet Macular Degeneration Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Wet Macular Degeneration Market Size (2019-2030)
6.2 North America Wet Macular Degeneration Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Wet Macular Degeneration Market Size by Country (2019-2024)
6.4 North America Wet Macular Degeneration Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Wet Macular Degeneration Market Size (2019-2030)
7.2 Europe Wet Macular Degeneration Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Wet Macular Degeneration Market Size by Country (2019-2024)
7.4 Europe Wet Macular Degeneration Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Wet Macular Degeneration Market Size (2019-2030)
8.2 Asia-Pacific Wet Macular Degeneration Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Wet Macular Degeneration Market Size by Region (2019-2024)
8.4 Asia-Pacific Wet Macular Degeneration Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Wet Macular Degeneration Market Size (2019-2030)
9.2 Latin America Wet Macular Degeneration Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Wet Macular Degeneration Market Size by Country (2019-2024)
9.4 Latin America Wet Macular Degeneration Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Wet Macular Degeneration Market Size (2019-2030)
10.2 Middle East & Africa Wet Macular Degeneration Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Wet Macular Degeneration Market Size by Country (2019-2024)
10.4 Middle East & Africa Wet Macular Degeneration Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer Inc.
11.1.1 Pfizer Inc. Company Detail
11.1.2 Pfizer Inc. Business Overview
11.1.3 Pfizer Inc. Wet Macular Degeneration Introduction
11.1.4 Pfizer Inc. Revenue in Wet Macular Degeneration Business (2019-2024)
11.1.5 Pfizer Inc. Recent Development
11.2 F. Hoffmann-La Roche AG
11.2.1 F. Hoffmann-La Roche AG Company Detail
11.2.2 F. Hoffmann-La Roche AG Business Overview
11.2.3 F. Hoffmann-La Roche AG Wet Macular Degeneration Introduction
11.2.4 F. Hoffmann-La Roche AG Revenue in Wet Macular Degeneration Business (2019-2024)
11.2.5 F. Hoffmann-La Roche AG Recent Development
11.3 Regeneron Pharmaceuticals, Inc.
11.3.1 Regeneron Pharmaceuticals, Inc. Company Detail
11.3.2 Regeneron Pharmaceuticals, Inc. Business Overview
11.3.3 Regeneron Pharmaceuticals, Inc. Wet Macular Degeneration Introduction
11.3.4 Regeneron Pharmaceuticals, Inc. Revenue in Wet Macular Degeneration Business (2019-2024)
11.3.5 Regeneron Pharmaceuticals, Inc. Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Detail
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Wet Macular Degeneration Introduction
11.4.4 Novartis AG Revenue in Wet Macular Degeneration Business (2019-2024)
11.4.5 Novartis AG Recent Development
11.5 Bausch Health Companies Inc.
11.5.1 Bausch Health Companies Inc. Company Detail
11.5.2 Bausch Health Companies Inc. Business Overview
11.5.3 Bausch Health Companies Inc. Wet Macular Degeneration Introduction
11.5.4 Bausch Health Companies Inc. Revenue in Wet Macular Degeneration Business (2019-2024)
11.5.5 Bausch Health Companies Inc. Recent Development
11.6 Apellis Pharmaceuticals Inc.
11.6.1 Apellis Pharmaceuticals Inc. Company Detail
11.6.2 Apellis Pharmaceuticals Inc. Business Overview
11.6.3 Apellis Pharmaceuticals Inc. Wet Macular Degeneration Introduction
11.6.4 Apellis Pharmaceuticals Inc. Revenue in Wet Macular Degeneration Business (2019-2024)
11.6.5 Apellis Pharmaceuticals Inc. Recent Development
11.7 GlaxoSmithKline plc
11.7.1 GlaxoSmithKline plc Company Detail
11.7.2 GlaxoSmithKline plc Business Overview
11.7.3 GlaxoSmithKline plc Wet Macular Degeneration Introduction
11.7.4 GlaxoSmithKline plc Revenue in Wet Macular Degeneration Business (2019-2024)
11.7.5 GlaxoSmithKline plc Recent Development
11.8 Ophthotech Corporation
11.8.1 Ophthotech Corporation Company Detail
11.8.2 Ophthotech Corporation Business Overview
11.8.3 Ophthotech Corporation Wet Macular Degeneration Introduction
11.8.4 Ophthotech Corporation Revenue in Wet Macular Degeneration Business (2019-2024)
11.8.5 Ophthotech Corporation Recent Development
11.9 Gilead Sciences, Inc.
11.9.1 Gilead Sciences, Inc. Company Detail
11.9.2 Gilead Sciences, Inc. Business Overview
11.9.3 Gilead Sciences, Inc. Wet Macular Degeneration Introduction
11.9.4 Gilead Sciences, Inc. Revenue in Wet Macular Degeneration Business (2019-2024)
11.9.5 Gilead Sciences, Inc. Recent Development
11.10 Alcon
11.10.1 Alcon Company Detail
11.10.2 Alcon Business Overview
11.10.3 Alcon Wet Macular Degeneration Introduction
11.10.4 Alcon Revenue in Wet Macular Degeneration Business (2019-2024)
11.10.5 Alcon Recent Development
11.11 Genzyme Corporation
11.11.1 Genzyme Corporation Company Detail
11.11.2 Genzyme Corporation Business Overview
11.11.3 Genzyme Corporation Wet Macular Degeneration Introduction
11.11.4 Genzyme Corporation Revenue in Wet Macular Degeneration Business (2019-2024)
11.11.5 Genzyme Corporation Recent Development
11.12 Boehringer Ingelheim GmbH
11.12.1 Boehringer Ingelheim GmbH Company Detail
11.12.2 Boehringer Ingelheim GmbH Business Overview
11.12.3 Boehringer Ingelheim GmbH Wet Macular Degeneration Introduction
11.12.4 Boehringer Ingelheim GmbH Revenue in Wet Macular Degeneration Business (2019-2024)
11.12.5 Boehringer Ingelheim GmbH Recent Development
11.13 EyeGate Pharmaceuticals, Inc.
11.13.1 EyeGate Pharmaceuticals, Inc. Company Detail
11.13.2 EyeGate Pharmaceuticals, Inc. Business Overview
11.13.3 EyeGate Pharmaceuticals, Inc. Wet Macular Degeneration Introduction
11.13.4 EyeGate Pharmaceuticals, Inc. Revenue in Wet Macular Degeneration Business (2019-2024)
11.13.5 EyeGate Pharmaceuticals, Inc. Recent Development
11.14 EyeCyte, Inc.
11.14.1 EyeCyte, Inc. Company Detail
11.14.2 EyeCyte, Inc. Business Overview
11.14.3 EyeCyte, Inc. Wet Macular Degeneration Introduction
11.14.4 EyeCyte, Inc. Revenue in Wet Macular Degeneration Business (2019-2024)
11.14.5 EyeCyte, Inc. Recent Development
11.15 PanOptica Inc
11.15.1 PanOptica Inc Company Detail
11.15.2 PanOptica Inc Business Overview
11.15.3 PanOptica Inc Wet Macular Degeneration Introduction
11.15.4 PanOptica Inc Revenue in Wet Macular Degeneration Business (2019-2024)
11.15.5 PanOptica Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Wet Macular Degeneration Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Lucentis
Table 3. Key Players of Eylea
Table 4. Key Players of Avastin
Table 5. Key Players of Others
Table 6. Global Wet Macular Degeneration Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Wet Macular Degeneration Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Wet Macular Degeneration Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Wet Macular Degeneration Market Share by Region (2019-2024)
Table 10. Global Wet Macular Degeneration Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Wet Macular Degeneration Market Share by Region (2025-2030)
Table 12. Wet Macular Degeneration Market Trends
Table 13. Wet Macular Degeneration Market Drivers
Table 14. Wet Macular Degeneration Market Challenges
Table 15. Wet Macular Degeneration Market Restraints
Table 16. Global Wet Macular Degeneration Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Wet Macular Degeneration Market Share by Players (2019-2024)
Table 18. Global Top Wet Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Wet Macular Degeneration as of 2023)
Table 19. Ranking of Global Top Wet Macular Degeneration Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Wet Macular Degeneration Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Wet Macular Degeneration Product Solution and Service
Table 23. Date of Enter into Wet Macular Degeneration Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Wet Macular Degeneration Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Wet Macular Degeneration Revenue Market Share by Type (2019-2024)
Table 27. Global Wet Macular Degeneration Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Wet Macular Degeneration Revenue Market Share by Type (2025-2030)
Table 29. Global Wet Macular Degeneration Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Wet Macular Degeneration Revenue Market Share by Application (2019-2024)
Table 31. Global Wet Macular Degeneration Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Wet Macular Degeneration Revenue Market Share by Application (2025-2030)
Table 33. North America Wet Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Wet Macular Degeneration Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Wet Macular Degeneration Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Wet Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Wet Macular Degeneration Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Wet Macular Degeneration Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Wet Macular Degeneration Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Wet Macular Degeneration Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Wet Macular Degeneration Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Wet Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Wet Macular Degeneration Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Wet Macular Degeneration Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Wet Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Wet Macular Degeneration Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Wet Macular Degeneration Market Size by Country (2025-2030) & (US$ Million)
Table 48. Pfizer Inc. Company Detail
Table 49. Pfizer Inc. Business Overview
Table 50. Pfizer Inc. Wet Macular Degeneration Product
Table 51. Pfizer Inc. Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)
Table 52. Pfizer Inc. Recent Development
Table 53. F. Hoffmann-La Roche AG Company Detail
Table 54. F. Hoffmann-La Roche AG Business Overview
Table 55. F. Hoffmann-La Roche AG Wet Macular Degeneration Product
Table 56. F. Hoffmann-La Roche AG Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)
Table 57. F. Hoffmann-La Roche AG Recent Development
Table 58. Regeneron Pharmaceuticals, Inc. Company Detail
Table 59. Regeneron Pharmaceuticals, Inc. Business Overview
Table 60. Regeneron Pharmaceuticals, Inc. Wet Macular Degeneration Product
Table 61. Regeneron Pharmaceuticals, Inc. Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)
Table 62. Regeneron Pharmaceuticals, Inc. Recent Development
Table 63. Novartis AG Company Detail
Table 64. Novartis AG Business Overview
Table 65. Novartis AG Wet Macular Degeneration Product
Table 66. Novartis AG Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)
Table 67. Novartis AG Recent Development
Table 68. Bausch Health Companies Inc. Company Detail
Table 69. Bausch Health Companies Inc. Business Overview
Table 70. Bausch Health Companies Inc. Wet Macular Degeneration Product
Table 71. Bausch Health Companies Inc. Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)
Table 72. Bausch Health Companies Inc. Recent Development
Table 73. Apellis Pharmaceuticals Inc. Company Detail
Table 74. Apellis Pharmaceuticals Inc. Business Overview
Table 75. Apellis Pharmaceuticals Inc. Wet Macular Degeneration Product
Table 76. Apellis Pharmaceuticals Inc. Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)
Table 77. Apellis Pharmaceuticals Inc. Recent Development
Table 78. GlaxoSmithKline plc Company Detail
Table 79. GlaxoSmithKline plc Business Overview
Table 80. GlaxoSmithKline plc Wet Macular Degeneration Product
Table 81. GlaxoSmithKline plc Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)
Table 82. GlaxoSmithKline plc Recent Development
Table 83. Ophthotech Corporation Company Detail
Table 84. Ophthotech Corporation Business Overview
Table 85. Ophthotech Corporation Wet Macular Degeneration Product
Table 86. Ophthotech Corporation Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)
Table 87. Ophthotech Corporation Recent Development
Table 88. Gilead Sciences, Inc. Company Detail
Table 89. Gilead Sciences, Inc. Business Overview
Table 90. Gilead Sciences, Inc. Wet Macular Degeneration Product
Table 91. Gilead Sciences, Inc. Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)
Table 92. Gilead Sciences, Inc. Recent Development
Table 93. Alcon Company Detail
Table 94. Alcon Business Overview
Table 95. Alcon Wet Macular Degeneration Product
Table 96. Alcon Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)
Table 97. Alcon Recent Development
Table 98. Genzyme Corporation Company Detail
Table 99. Genzyme Corporation Business Overview
Table 100. Genzyme Corporation Wet Macular Degeneration Product
Table 101. Genzyme Corporation Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)
Table 102. Genzyme Corporation Recent Development
Table 103. Boehringer Ingelheim GmbH Company Detail
Table 104. Boehringer Ingelheim GmbH Business Overview
Table 105. Boehringer Ingelheim GmbH Wet Macular Degeneration Product
Table 106. Boehringer Ingelheim GmbH Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)
Table 107. Boehringer Ingelheim GmbH Recent Development
Table 108. EyeGate Pharmaceuticals, Inc. Company Detail
Table 109. EyeGate Pharmaceuticals, Inc. Business Overview
Table 110. EyeGate Pharmaceuticals, Inc. Wet Macular Degeneration Product
Table 111. EyeGate Pharmaceuticals, Inc. Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)
Table 112. EyeGate Pharmaceuticals, Inc. Recent Development
Table 113. EyeCyte, Inc. Company Detail
Table 114. EyeCyte, Inc. Business Overview
Table 115. EyeCyte, Inc. Wet Macular Degeneration Product
Table 116. EyeCyte, Inc. Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)
Table 117. EyeCyte, Inc. Recent Development
Table 118. PanOptica Inc Company Detail
Table 119. PanOptica Inc Business Overview
Table 120. PanOptica Inc Wet Macular Degeneration Product
Table 121. PanOptica Inc Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)
Table 122. PanOptica Inc Recent Development
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Wet Macular Degeneration Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Wet Macular Degeneration Market Share by Type: 2023 VS 2030
Figure 3. Lucentis Features
Figure 4. Eylea Features
Figure 5. Avastin Features
Figure 6. Others Features
Figure 7. Global Wet Macular Degeneration Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Wet Macular Degeneration Market Share by Application: 2023 VS 2030
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Research Institutes Case Studies
Figure 12. Academic Institutes Case Studies
Figure 13. Wet Macular Degeneration Report Years Considered
Figure 14. Global Wet Macular Degeneration Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global Wet Macular Degeneration Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Wet Macular Degeneration Market Share by Region: 2023 VS 2030
Figure 17. Global Wet Macular Degeneration Market Share by Players in 2023
Figure 18. Global Top Wet Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Wet Macular Degeneration as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by Wet Macular Degeneration Revenue in 2023
Figure 20. North America Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America Wet Macular Degeneration Market Share by Country (2019-2030)
Figure 22. United States Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Wet Macular Degeneration Market Share by Country (2019-2030)
Figure 26. Germany Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Wet Macular Degeneration Market Share by Region (2019-2030)
Figure 34. China Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Wet Macular Degeneration Market Share by Country (2019-2030)
Figure 42. Mexico Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Wet Macular Degeneration Market Share by Country (2019-2030)
Figure 46. Turkey Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Pfizer Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)
Figure 49. F. Hoffmann-La Roche AG Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)
Figure 50. Regeneron Pharmaceuticals, Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)
Figure 51. Novartis AG Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)
Figure 52. Bausch Health Companies Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)
Figure 53. Apellis Pharmaceuticals Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)
Figure 54. GlaxoSmithKline plc Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)
Figure 55. Ophthotech Corporation Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)
Figure 56. Gilead Sciences, Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)
Figure 57. Alcon Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)
Figure 58. Genzyme Corporation Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)
Figure 59. Boehringer Ingelheim GmbH Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)
Figure 60. EyeGate Pharmaceuticals, Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)
Figure 61. EyeCyte, Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)
Figure 62. PanOptica Inc Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
